NCT02677805 - Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II | Biotech Hunter

Enrollment

251

Participants

Timeline

Start Date

March 30, 2016

Primary Completion Date

September 15, 2016

Study Completion Date

November 3, 2017

Conditions

Glabellar Frown Lines

Interventions

DRUG

Botulinum Toxin A

Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area

DRUG

Placebo

injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area

DRUG

Botulinum Toxin A - Open Label

Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area

Trial Locations (7)

Center for Clinical and Cosmetic Research, Aventura

Skintastic Medical, Plano

California Dermatology & Clinical Research Institute, Encinitas

Holcomb Kreithen Plastic Surgery, Sarasota

Skin Laser And Surgery Specialists Of New York & New Jersey, Hillsborough

The Center for Dermatology, Cosmetic & Laser Surger, Mount Kisco

Lorenc Aesthetic Plastic Surgery Center, New York